From the Guidelines
Accrufer is not mentioned in the provided evidence, and therefore, its use or recommendation cannot be made based on the given studies. The provided evidence focuses on delirium prevention and therapy in critically ill patients, discussing non-pharmacological interventions such as multimodal sensory, cognitive, and emotional stimulation 1. Some key points from the evidence include:
- Recommendation 5 suggests that interventions for delirium prophylaxis ought to include multimodal sensory, cognitive, and emotional stimulation, with a Grade of recommendation A and High quality of evidence 1.
- Recommendation 6 emphasizes the importance of reducing stress, improving communication, and family care, using the ABCDEF-bundle combined with regular delirium assessments, with a Grade of recommendation A and High quality of evidence 1. However, since Accrufer is not discussed in the provided evidence, its safety and efficacy cannot be determined based on this information. In real-life clinical practice, when the evidence is equivocal or not available, a decision would be made on the side of caution, considering the patient's specific needs and medical history. Given the lack of information on Accrufer in the provided studies, it is essential to consult other reliable sources or guidelines for its recommended use.
From the Research
Definition and Uses of Accrufer
- Accrufer, also known as Ferric Maltol, is an oral iron formulation used for the treatment of iron deficiency anemia (IDA) in adults 2, 3.
- It is a ferric, non-salt-based oral iron formulation that has demonstrated improved tolerance in patients with previous intolerance to other iron formulations 3.
- Accrufer is used to treat IDA in patients with inflammatory bowel disease (IBD) and chronic kidney disease (CKD) 3, 4, 5, 6.
Mechanism of Action and Efficacy
- Accrufer works by forming stable iron complexes that can transfer iron across cell membranes and increase iron absorption in animals 2.
- Studies have shown that Accrufer is effective in increasing hemoglobin levels and improving iron parameters in patients with IDA 3, 4, 5, 6.
- Accrufer has been compared to intravenous ferric carboxymaltose and has shown comparable long-term effectiveness for hemoglobin and ferritin over 52 weeks 6.
Safety and Tolerability
- Accrufer is generally well-tolerated, with common adverse effects being gastrointestinal intolerance 3, 4, 6.
- Treatment-emergent adverse events have been reported in patients taking Accrufer, but the majority of patients are able to continue treatment without discontinuation 6.
- Accrufer has been shown to be safe and effective for use in patients with CKD and IBD, with a low risk of adverse events 4, 5.